STOCK TITAN

Belite Bio CMO reports sale of 2,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Belite Bio, Inc. (BLTE) Chief Medical Officer Hendrik Peter Scholl reported that Bioptima Ltd. indirectly sold 2,000 American depositary shares on November 12, 2026, in four 500-share transactions at $162.0394, $164.6839, $166.8195 and $170.4094 per share. The sales were made under a Rule 10b5-1 trading plan adopted June 25, 2026. Each American depositary share represents one ordinary share.

Insider Scholl Hendrik Peter
Role Chief Medical Officer
Sold 2,000 shs ($332K)
Type Security Shares Price Value
Sale American depositary share F1, F2 500 $162.0394 $81K
Sale American depositary share F1, F2 500 $164.6839 $82K
Sale American depositary share F1, F2 500 $166.8195 $83K
Sale American depositary share F1, F2 500 $170.4094 $85K
Holdings After Transaction: American depositary share — 12,500 shares (Indirect, By Bioptima Ltd.)
Footnotes (2)
  1. F1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
  2. F2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026.
American depositary shares sold 2,000 shares Sold indirectly by Bioptima Ltd. on November 12, 2026
Shares per transaction 500 shares Each of four sales on November 12, 2026
Sale price per share $162.0394 One 500-share sale on November 12, 2026
Sale price per share $164.6839 One 500-share sale on November 12, 2026
Sale price per share $166.8195 One 500-share sale on November 12, 2026
Sale price per share $170.4094 One 500-share sale on November 12, 2026
American depositary share financial
"Each American depositary share represents one ordinary share"
An American Depositary Share (ADS) is a U.S.-listed certificate that represents a specified number of shares in a foreign company, held by a custodian bank; it works like a receipt that allows U.S. investors to buy and trade foreign equity on American exchanges without dealing with another country’s markets. Investors care because ADSs make foreign stocks easier to access, improve liquidity and settlement in dollars, and can affect dividend payments, voting rights and regulatory oversight compared with buying the underlying foreign shares directly.
Rule 10b5-1 trading plan regulatory
"Sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many BLTE shares did Bioptima Ltd. sell, and at what prices?

Bioptima Ltd. sold 2,000 American depositary shares in four 500-share transactions on November 12, 2026, at $162.0394, $164.6839, $166.8195 and $170.4094 per share. The sales were made under a Rule 10b5-1 trading plan adopted June 25, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Scholl Hendrik Peter

(Last)(First)(Middle)
GOTTHARDSTRASSE 26

(Street)
ZUGSWITZERLAND6300

(City)(State)(Zip)

SWITZERLAND

(Country)
2. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Medical Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/12/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
American depositary share(1)11/12/2026S(2)500D$162.039414,000IBy Bioptima Ltd.
American depositary share(1)11/12/2026S(2)500D$164.683913,500IBy Bioptima Ltd.
American depositary share(1)11/12/2026S(2)500D$166.819513,000IBy Bioptima Ltd.
American depositary share(1)11/12/2026S(2)500D$170.409412,500IBy Bioptima Ltd.
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the issuer.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/25/2026.
/s/ Hendrik Peter Scholl11/16/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading